Jarrad Mattieu Aguirre
CIK: 0002150331
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)1 (50.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)1 (50.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
LYEL
Lyell Immunopharma, Inc.
Officer
Discretionary Trading P&L
Holdings
About Aguirre Jarrad Mattieu
Aguirre Jarrad Mattieu (SEC CIK 0002150331) files insider reports with the SEC as Chief Medical Officer of Lyell Immunopharma, Inc. (LYEL).
Signal8 holds 3 ownership filings by Aguirre Jarrad Mattieu (1 Form 3, 2 Form 4), filed between Sep 10, 2026 and Oct 13, 2026. Those filings report 2 transactions, from Sep 10, 2026 to Oct 12, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Aguirre Jarrad Mattieu's filings is in SOUTH SAN FRANCISCO, CA.
Recent filings by Aguirre Jarrad Mattieu
Other insiders filing for Lyell Immunopharma, Inc. (LYEL)
- Shook David, Chief Medical Officer
- Seely Lynn, President and CEO
- Hill Stephen J., Chief Operating Officer
- Lee Gary K., Chief Scientific Officer
- Bulis Veronica Sanchez, VP, Corporate Controller
- Innovative Cellular Therapeutics Holdings Ltd, 10% Owner